ExploreWatchlistsPricing
  1. US-listed companies
  2. FATE THERAPEUTICS INC
  3. Financials
  4. Stock-based compensation

FATE THERAPEUTICS INC (FATE)

Market cap
$135.27M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202441-4.52%
Dec 31, 202343-44.80%
Dec 31, 202279+44.83%
Dec 31, 202154+76.78%
Dec 31, 202031+76.64%
Dec 31, 201917+176.66%
Dec 31, 20186+74.51%
Dec 31, 20174+13.25%
Dec 31, 20163+32.67%
Dec 31, 20152-1.40%
Dec 31, 20142+4.78%
Dec 31, 20132

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat